Showing 1 posts of 1 posts found.
GlaxoSmithKline posted a 4% slide in revenue for the second quarter today as its recovery from a slew of patent …
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
Bramacare opens supported-living facility for eating disorder recovery
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical